Stock CRXM TAXUS CARDIUM PHARMACEUTICALS GROUP INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Taxus Cardium Pharmaceuticals Group Inc OTC Bulletin Board

Equities

CRXM

US1419163043

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Taxus Cardium Pharmaceuticals Group Inc
2022 Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
2021 Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GENE BIOTHERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
AQ
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt
CI
GENE BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
CI
GENE BIOTHERAPEUTICS : Changes in Registrant's Certifying Accountant (form 8-K/A)
AQ
GENE BIOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant (form 8-K)
AQ
GENE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
Gene Biotherapeutics, Inc. Announces Resignation of Murray H. Hutchison from the Board
CI
GENE BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Gene Biotherapeutics Inc. Enters into an Agreement with Fujifilm Diosynth Biotechnologies to Manufacture the Generx Angiogenic Gene Therapy Product
CI
GENE BIOTHERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
GENE BIOTHERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Gene Biotherapeutics, Inc. Announces Management Changes
CI
Gene Biotherapeutics, Inc. Appoints James L. Grainer as Chief Financial Officer
CI
Gene Biotherapeutics, Inc. announced that it has received $1.7 million in funding from Nostrum Pharmaceuticals LLC
CI
Gene Biotherapeutics Inc. Announces Retirement of Gerald J. Lewis from its Board of Directors
CI
Gene Biotherapeutics Inc. Enters into an Agreement with the Olaregen Therapeutix Inc
CI
Gene Biotherapeutics Mulls Acquisitions
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRXM Stock
  4. CRXM Stock
  5. News Taxus Cardium Pharmaceuticals Group Inc